KIT and PDGFRA Mutations and the Risk of GI Stromal Tumor Recurrence

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F15%3A00082981" target="_blank" >RIV/00216224:14110/15:00082981 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1200/JCO.2014.57.4970" target="_blank" >http://dx.doi.org/10.1200/JCO.2014.57.4970</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1200/JCO.2014.57.4970" target="_blank" >10.1200/JCO.2014.57.4970</a>

Jazyk výsledku

angličtina

Název v původním jazyce

KIT and PDGFRA Mutations and the Risk of GI Stromal Tumor Recurrence

Popis výsledku v původním jazyce

Purpose Mutated KIT and platelet-derived growth factor alpha gene (PDGFRA) drive GI stromal tumor (GIST) oncogenesis, but the clinical significance of their single mutations is known incompletely. Patients and Methods We identified 11 population-based series of patients with GIST through a literature search and pooled individual data from 3,067 patients treated with macroscopically complete tumor excision. Mutation analysis was done from 1,505 tumors. We analyzed associations between KIT and PDGFRA mutations and recurrence-free survival (RFS) in the subsets in which patients were treated with surgery alone. Results We identified 301 different single mutations in KIT and 33 in PDGFRA. Patients with PDGFRA mutations had more favorable RFS than those withKIT mutations (hazard ratio, 0.34; P = .004). Only one of the 35 GISTs with KIT exon 11 duplication mutations recurred.

Název v anglickém jazyce

KIT and PDGFRA Mutations and the Risk of GI Stromal Tumor Recurrence

Popis výsledku anglicky

Purpose Mutated KIT and platelet-derived growth factor alpha gene (PDGFRA) drive GI stromal tumor (GIST) oncogenesis, but the clinical significance of their single mutations is known incompletely. Patients and Methods We identified 11 population-based series of patients with GIST through a literature search and pooled individual data from 3,067 patients treated with macroscopically complete tumor excision. Mutation analysis was done from 1,505 tumors. We analyzed associations between KIT and PDGFRA mutations and recurrence-free survival (RFS) in the subsets in which patients were treated with surgery alone. Results We identified 301 different single mutations in KIT and 33 in PDGFRA. Patients with PDGFRA mutations had more favorable RFS than those withKIT mutations (hazard ratio, 0.34; P = .004). Only one of the 35 GISTs with KIT exon 11 duplication mutations recurred.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of clinical oncology

ISSN

0732-183X

e-ISSN

—

Svazek periodika

33

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

15

Strana od-do

"634"-"U155"

Kód UT WoS článku

000352523800019

EID výsledku v databázi Scopus

—